RBC Capital analyst Luva Issi reiterated an Outperform rating and $100.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'April 28, 2026 2:00 PM Barclays on BridgeBio Pharma (BBIO): 'We see buying opportunity on weakness, reiterate top idea'April 28, 2026 12:14 PM TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'April 28, 2026 11:46 AM